Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors

RW Kim, M Lam, K Abuabara, EL Simpson… - American Journal of …, 2024 - Springer
Therapeutic options for people with moderate or severe atopic dermatitis refractory to topical
therapy have rapidly expanded in recent years. These new targeted immunomodulatory …

Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues

M Gatti, E Turrini, E Raschi, P Sestili, C Fimognari - Pharmaceuticals, 2021 - mdpi.com
We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients

DE Dulek, RC Fuhlbrigge, AC Tribble… - Journal of the …, 2020 - academic.oup.com
Background Immune-mediated lung injury and systemic hyperinflammation are
characteristic of severe and critical coronavirus disease 2019 (COVID-19) in adults …

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

E Favoino, M Prete, G Catacchio, P Ruscitti… - Autoimmunity …, 2021 - Elsevier
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway is
an important intracellular route through which many different extracellular soluble …

JAK-STAT pathway inhibitors in dermatology

HA Miot, PR Criado, CCS Castro, M Ianhez… - Anais brasileiros de …, 2023 - SciELO Brasil
The JAK-STAT signaling pathway mediates important cellular processes such as immune
response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that …

Emerging place of JAK inhibitors in the treatment of inborn errors of immunity

J Hadjadj, ML Frémond, B Neven - Frontiers in Immunology, 2021 - frontiersin.org
Among inborn errors of immunity (IEIs), some conditions are characterized by inflammation
and autoimmunity at the front line and are particularly challenging to treat. Monogenic …

JAK inhibition in Juvenile idiopathic arthritis (JIA): better understanding of a promising therapy for refractory cases

I Melki, ML Frémond - Journal of Clinical Medicine, 2023 - mdpi.com
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases with probably
differential underlying physiopathology. Despite the revolutionary era of biologics, some …

Pharmacology of inhibitors of Janus kinases–Part 1: Pharmacokinetics

A Eichner, J Wohlrab - JDDG: Journal der Deutschen …, 2022 - Wiley Online Library
The use of Janus kinase inhibitors for the treatment of chronic inflammatory diseases is
increasingly establishing itself as a treatment option for several indications. In order to make …

Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies

M Biswas, N Sawajan, T Rungrotmongkol… - Frontiers in …, 2022 - frontiersin.org
Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19)
pandemic situations without establishing clinical effectiveness or tailoring safety. A …

[HTML][HTML] Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma

J Tachet, F Versace, T Mercier, T Buclin… - … of Chromatography B, 2023 - Elsevier
Janus kinase inhibitors (JAKi) are oral small molecules used in the treatment of a broad
spectrum of autoimmune and myeloproliferative diseases. JAKi exhibit significant intra-and …